Lookups / Rulings
N318724
The tariff classification of Fulvestrant Injection in dosage form
HS3004390050
DateApr 26, 2021
Ruling text
N318724 April 27, 2021 CLA-2-30:OT:RR:NC:N3:138 CATEGORY: Classification; Country of Origin TARIFF NO.: 3004.39.0050 Mr. Pradeep Shah Zydus Pharmaceuticals USA Inc. 73 Route 31 North Pennington, NJ 08534 RE: The tariff classification of Fulvestrant Injection in dosage form Dear Mr. Shah: In your letter dated April 5, 2021, you requested a tariff classification and country of origin ruling. Fulvestrant Injection, imported in 50 mg/mL, is an estrogen receptor antagonist. It is indicated for the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. The applicable subheading for the Fulvestrant Injection in dosage form will be 3004.39.0050, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other, containing hormones or other products of heading 2937: Other: Other.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. You also requested a country of origin ruling. You stated that the active pharmaceutical ingredient (API), Fulvestrant, is manufactured in Malta and that the finished Fulvestrant Injection in dosage form is made in India. In India, the Fulvestrant will be mixed with various inactive ingredients to produce the final Fulvestrant Injection in dosage form. Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production or growth of any article of foreign origin entering the United States. Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part;…. A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact. See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986). In this case, we find the mixing of the active ingredient Fulvestrant (made in Malta) with the inactive ingredients into the Fulvestrant Injection in dosage form in India does not result in a substantial transformation and the country of origin will be Malta. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at judy.h.lee@cbp.dhs.gov. Sincerely, Steven A. Mack Director National Commodity Specialist Division
Related rulings on this HS code
Top 10 other CROSS rulings on HS 300439, newest first.
- N362938Aug 05, 20263004390080-
- N360873May 14, 20263004390055-
- N360491May 05, 20263004390055-
- N359359Mar 30, 20263004390020-
- N357260Jan 14, 20263004390050-
- N356282Dec 16, 20253004390050-
- N355138Nov 16, 20253004390050-
- N353894Oct 16, 20253004390050-
- N349904Jun 26, 20253004390050-
- N348001May 14, 20253004390050-
